Successful treatment of kaposiform hemangioendothelioma with everolimus

Pediatric Blood and Cancer

Volumn 62, Issue 3, 2015, Pages 536-538

  Uno, Teruaki ^a   Ito, Shuichi ^a   Nakazawa, Atsuko ^a   Miyazaki, Osamu ^a   Mori, Tetsuya ^a   Terashima, Keita ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Kasabach Merritt phenomenon; MTOR; Rapamycin; Sirolimus; Vascular tumor

Indexed keywords

EVEROLIMUS; FIBRINOGEN; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISOLONE; PROPRANOLOL; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADD ON THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURGERY; CASE REPORT; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FEMUR TUMOR; HEMANGIOENDOTHELIOMA; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; KAPOSI SARCOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; LONG TERM EXPOSURE; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; PAIN SEVERITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; STOMATITIS; TIME TO TREATMENT; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR RESISTANCE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG RESISTANCE; KASABACH-MERRITT SYNDROME; PATHOLOGY; SARCOMA, KAPOSI;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG RESISTANCE, NEOPLASM; HEMANGIOENDOTHELIOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KASABACH-MERRITT SYNDROME; MALE; PREDNISOLONE; PROPRANOLOL; SARCOMA, KAPOSI; SIROLIMUS; VINCRISTINE;

EID: 84921370511     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25241     Document Type: Article

References (10)

1. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC 3rd, Kaposiform hemangioendothelioma: Atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162:142-147.
2. Iwami D, Shimaoka S, Mochizuki I, Sakuma T. Kaposiform hemangioendothelioma of the mediastinum in a 7-month-old boy: A case report. J Pediatr Surg 2006; 41:1486-1488.
3. Drolet BA, Trenor CC 3rd, Brandao LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163:285-291.
4. Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55:1396-1398.
5. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018-1024.
6. Granger CV, Hamilton BB. UDS report. The Uniform Data System for Medical Rehabilitation Report of First Admissions for 1990. Am J Physi Med Rehabil 1992; 71:108-113.
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clinical pharmacokinetics 2004; 43:83-95.
8. Hartford CM, Ratain MJ. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82:381-388.
9. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125-132.
10. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 2013; 80:574-580.